Also known as Saphris
Asenapine (INN, trade names Saphris, Sycrest) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 merger with Organon International. Development of the drug, through Phase III trials, began while Organon was still a part of Akzo Nobel. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in clinical trials of asenapine, and the FDA accepted the manufacturer's NDA on November 26, 2007 for standard review.Source: Wikipedia
Estimated Total Cost: $439.04 for an average of 28 days supply
Patients are most commonly prescribed asenapine to treat bipolar disorder, rabies, blastomycosis, and west nile virus.
Patients taking asenapine most commonly experience side effects like headache, insomnia, and constipation.